ACE-031

A soluble ActRIIB-Fc fusion protein studied in preclinical muscle and cellular signaling research models.

Molecular Profile

Type
Recombinant Fc-fusion protein (ActRIIB extracellular domain - human IgG1 Fc; disulfide-linked homodimer)
Molecular weight
~58.4 kDa per monomer (glycosylated)
CAS number
1169766-01-1
Amino acids
343
Modification
Disulfide-linked homodimer. Each 343-residue chain comprises the ACVR2B extracellular domain (residues 1-115), a triglycyl linker (116-118), and a human IgG1 Fc (119-343); seven intrachain disulfide bridges per chain, two interchain disulfide bridges joining the two chains, and three N-glycosylation sites per chain.

Mechanism & Target Class

A soluble decoy receptor. The extracellular ACVR2B domain binds circulating TGF-beta superfamily ligands - myostatin (GDF-8), activin A, activin B, and GDF-11 - so that they do not engage membrane-bound type II activin receptors and recruit type I receptors (ALK4/ALK5), modulating SMAD2/3 signaling in the activin-receptor pathway in skeletal muscle. The construct also binds the vascular regulators BMP-9/BMP-10, with comparatively lower affinity for BMP-2/BMP-7. The IgG1 Fc drives dimerization and confers extended circulation.

Storage & Handling

Lyophilized
-20C (-80C long term); supplied lyophilized. Lyophilized powder is stable when kept sealed and dry.
Handling
Aliquot to minimize freeze-thaw; protect from light; confirm handling against the specific lot Certificate of Analysis.

Primary Database

DrugBank DB15116 ↗

References (19)

  1. Reviews

    1

    Lee SJ. (2023). Annual Review of Physiology

    DOI: 10.1146/annurev-physiol-012422-112116PubMed 36266260

  2. 2

    Rybalka E, et al. (2020). Cells

    DOI: 10.3390/cells9122657PubMed 33321734

  3. 3

    Suh J, Lee YS. (2020). Journal of Bone Metabolism

    DOI: 10.11005/jbm.2020.27.3.151PubMed 32911580

  4. Clinical

    4

    Campbell C, et al. (2017). Muscle & Nerve

    DOI: 10.1002/mus.25268PubMed 27462804

  5. 5

    Attie KM, et al. (2013). Muscle & Nerve

    DOI: 10.1002/mus.23539PubMed 23169607

  6. 6

    ClinicalTrials.gov (A031-01). ClinicalTrials.gov

    NCT00755638

  7. 7

    ClinicalTrials.gov (A031-02). ClinicalTrials.gov

    NCT00952887

  8. 8

    ClinicalTrials.gov (A031-03). ClinicalTrials.gov

    NCT01099761

  9. 9

    ClinicalTrials.gov (A031-06). ClinicalTrials.gov

    NCT01239758

  10. Primary research

    10

    Reichel C, et al. (2025). Drug Testing and Analysis

    DOI: 10.1002/dta.3898PubMed 40312924

  11. 11

    Lach-Trifilieff E, et al. (2014). Molecular and Cellular Biology

    DOI: 10.1128/MCB.01307-13PubMed 24298022

  12. 12

    Pistilli EE, et al. (2011). American Journal of Pathology

    DOI: 10.1016/j.ajpath.2010.11.071PubMed 21356379

  13. 13

    Cadena SM, et al. (2010). Journal of Applied Physiology

    DOI: 10.1152/japplphysiol.00866.2009PubMed 20466801

  14. 14

    Sako D, et al. (2010). Journal of Biological Chemistry

    DOI: 10.1074/jbc.M110.114959PubMed 20385559

  15. 15

    Zhou X, et al. (2010). Cell

    DOI: 10.1016/j.cell.2010.07.011PubMed 20723755

  16. 16

    Koncarevic A, et al. (2010). Endocrinology

    DOI: 10.1210/en.2010-0134PubMed 20573726

  17. 17

    Pistilli EE, et al. (2010). American Journal of Physiology - Regulatory, Integrative and Comparative Physiology

    DOI: 10.1152/ajpregu.00138.2009PubMed 19864340

  18. 18

    Lee SJ, et al. (2005). Proceedings of the National Academy of Sciences

    DOI: 10.1073/pnas.0505996102PubMed 16330774

  19. 19

    Lee SJ, McPherron AC. (2001). Proceedings of the National Academy of Sciences

    DOI: 10.1073/pnas.151270098PubMed 11459935